Advanced

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Ahrén, Bo LU ; Foley, James Edward; Dejager, Sylvie; Akacha, Mouna; Shao, Qing; Heimann, Guenter; Dworak, Markus and Schweizer, Anja (2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders
Abstract
In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased hypoglycemia with glimepiride was driven by the 6 mg/day dose; it was therefore of interest to assess whether the risk of hypoglycemia is also different between vildagliptin and a low (2 mg/day) dose of glimepiride.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetes therapy : research, treatment and education of diabetes and related disorders
publisher
Springer
external identifiers
  • pmid:25230877
  • scopus:84919650730
ISSN
1869-6953
DOI
10.1007/s13300-014-0082-y
language
English
LU publication?
yes
id
c8897711-3fa9-4a57-bae9-592d7ccdf5d0 (old id 4691349)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25230877?dopt=Abstract
date added to LUP
2014-10-07 19:55:11
date last changed
2017-10-01 03:59:37
@article{c8897711-3fa9-4a57-bae9-592d7ccdf5d0,
  abstract     = {In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased hypoglycemia with glimepiride was driven by the 6 mg/day dose; it was therefore of interest to assess whether the risk of hypoglycemia is also different between vildagliptin and a low (2 mg/day) dose of glimepiride.},
  author       = {Ahrén, Bo and Foley, James Edward and Dejager, Sylvie and Akacha, Mouna and Shao, Qing and Heimann, Guenter and Dworak, Markus and Schweizer, Anja},
  issn         = {1869-6953},
  language     = {eng},
  month        = {09},
  publisher    = {Springer},
  series       = {Diabetes therapy : research, treatment and education of diabetes and related disorders},
  title        = {Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?},
  url          = {http://dx.doi.org/10.1007/s13300-014-0082-y},
  year         = {2014},
}